INT111113

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2003
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 9.17
Pain Relevance 2.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CYP19A1) small molecule metabolic process (CYP19A1) endoplasmic reticulum (CYP19A1)
cytoplasm (CYP19A1)
Anatomy Link Frequency
stroma 1
embryo 1
CYP19A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Buprenorphine 10 94.44 High High
cytokine 51 87.68 High High
Inflammation 63 87.28 High High
endometriosis 196 85.20 High High
methotrexate 1 76.72 Quite High
agonist 161 71.36 Quite High
opiate 1 71.04 Quite High
corticosteroid 32 69.28 Quite High
antagonist 180 57.44 Quite High
cva 43 53.20 Quite High
Disease Link Frequency Relevance Heat
Endometriosis 228 99.84 Very High Very High Very High
Cancer 228 97.56 Very High Very High Very High
Reprotox - General 1 299 95.84 Very High Very High Very High
Suicidal Behaviour 4 95.68 Very High Very High Very High
Breast Disease 18 94.56 High High
Exanthema 6 92.16 High High
Fatigue 19 91.68 High High
Dizziness 6 90.96 High High
Reprotox - General 2 39 90.56 High High
Ataxia 6 90.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Compounds with selective affinity to the enzyme aromatase (CYP 19), namely 4-hydroxyandrostenedione and aminoglutethimide, caused >70% inhibition of norBUP formation.
CYP 19 Binding (affinity) of
1) Confidence 0.36 Published 2003 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 12808001 Disease Relevance 0 Pain Relevance 0.80
Thus, the individual trials demonstrate a trend or even a significant difference in favor of the third-generation aromatase inhibitors in one or more efficacy end points; in addition, the aromatase inhibitors were shown to be associated with improved tolerability versus comparator endocrine therapy in these randomized trials.
aromatase Binding (associated) of
2) Confidence 0.35 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001219 Disease Relevance 0.08 Pain Relevance 0.03
We investigated the idea of combining an aromatase inhibitor with FSH injections to reduce the dose of FSH required to achieve optimum controlled ovarian hyperstimulation, without adverse antiestrogenic effects [431,432].
aromatase Binding (inhibitor) of
3) Confidence 0.29 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.16 Pain Relevance 0
Steroidal aromatase inhibitors are androstenedione analogues that act as a false substrate and bind irreversibly to the androgen-binding site of the enzyme [398].
aromatase Binding (bind) of
4) Confidence 0.28 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.62 Pain Relevance 0.03
Data have been accumulating regarding the absence of deleterious effects in association with aromatase inhibitor treatment on follicle/oocyte maturation and embryo development in mice [492,493].
aromatase Binding (association) of in embryo
5) Confidence 0.28 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0
AIs are categorized in two types, non-steroidal and steroidal, and differ in their modes of interaction with the aromatase-enzymatic complex and its inactivation.
aromatase Binding (interaction) of
6) Confidence 0.26 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682397 Disease Relevance 0.30 Pain Relevance 0.08
Non-steroidal aromatase inhibitors exert their function through binding to the heme moiety of the cytochrome P450 enzyme [399].
Non-steroidal aromatase Binding (binding) of
7) Confidence 0.25 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.67 Pain Relevance 0.03
As a steroidal ai, exemestane has a structure similar to androstenedione and competitively binds with aromatase.
aromatase Binding (binds) of
8) Confidence 0.24 Published 2008 Journal Current Oncology Section Body Doc Link PMC2216420 Disease Relevance 0.25 Pain Relevance 0.04
The steroidal AI exemestane binds to aromatase irreversibly.
aromatase Binding (binds) of
9) Confidence 0.22 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 1.30 Pain Relevance 0.18
Adjuvant therapy with aromatase inhibitors vs. tamoxifen
aromatase Binding (therapy) of
10) Confidence 0.17 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 0.48 Pain Relevance 0
Each successive generation has been associated with higher specificity for the aromatase enzyme (Figure 3), fewer adverse events, and greater suppression of aromatase activity.
aromatase Binding (associated) of
11) Confidence 0.17 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 1.29 Pain Relevance 0.26
Each successive generation has been associated with higher specificity for the aromatase enzyme (Figure 3), fewer adverse events, and greater suppression of aromatase activity.
aromatase enzyme Binding (associated) of
12) Confidence 0.17 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 1.26 Pain Relevance 0.26
Non-steroidal AIs reversibly bind to the aromatase enzyme and include anastrozole and letrozole.
aromatase enzyme Binding (bind) of
13) Confidence 0.17 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 1.32 Pain Relevance 0.19
Neoadjuvant therapy with aromatase inhibitors vs. tamoxifen
aromatase Binding (therapy) of
14) Confidence 0.17 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 0.56 Pain Relevance 0
Moreover, the enzyme aromatase is exclusively found in endometriotic stroma [105] and provides E1, which is further converted to E2 by 17?
aromatase Binding (found) of in stroma associated with endometriosis
15) Confidence 0.03 Published 2007 Journal Semin Immunopathol Section Body Doc Link PMC2668599 Disease Relevance 0.86 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox